|
US5801195A
(en)
*
|
1994-12-30 |
1998-09-01 |
Celgene Corporation |
Immunotherapeutic aryl amides
|
|
DE69624081T2
(de)
*
|
1995-12-20 |
2003-06-12 |
Agouron Pharmaceuticals, Inc. |
Matrix-metalloprotease Inhibitoren
|
|
US6747027B1
(en)
|
1996-07-22 |
2004-06-08 |
Pharmacia Corporation |
Thiol sulfonamide metalloprotease inhibitors
|
|
DE69729007T2
(de)
*
|
1996-08-07 |
2005-04-07 |
Darwin Discovery Ltd., Slough |
Hydroxamsäure- und carbonsäure-derivate mit mmp und tnf hemmender wirkung
|
|
US6566384B1
(en)
|
1996-08-07 |
2003-05-20 |
Darwin Discovery Ltd. |
Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
|
|
WO1998013340A1
(en)
*
|
1996-09-27 |
1998-04-02 |
Pharmacia & Upjohn Company |
β-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS
|
|
US5962481A
(en)
*
|
1996-10-16 |
1999-10-05 |
American Cyanamid Company |
Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
|
|
US5977408A
(en)
*
|
1996-10-16 |
1999-11-02 |
American Cyanamid Company |
Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
|
|
US6228869B1
(en)
|
1996-10-16 |
2001-05-08 |
American Cyanamid Company |
Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
|
|
US5929097A
(en)
*
|
1996-10-16 |
1999-07-27 |
American Cyanamid Company |
Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
|
|
US6548524B2
(en)
|
1996-10-16 |
2003-04-15 |
American Cyanamid Company |
Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
|
|
AU768182B2
(en)
*
|
1996-12-19 |
2003-12-04 |
Aventis Pharmaceuticals Inc. |
Process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and alpha,beta-unsaturated carboxylic acid and aldehyde compounds
|
|
US6392010B1
(en)
|
1996-12-19 |
2002-05-21 |
Aventis Pharmaceuticals Inc. |
Process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and αβ-unsaturated carboxylic acid and aldehyde compounds
|
|
US6133409A
(en)
*
|
1996-12-19 |
2000-10-17 |
Aventis Pharmaceuticals Products Inc. |
Process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and αβ-unsaturated carboxylic acid and aldehyde compounds
|
|
EP1674484A3
(en)
*
|
1996-12-19 |
2010-06-30 |
Aventis Pharmaceuticals Inc. |
Process for the solid phase synthesis of aldehydes, ketones, oximes, amines and hydroxamic acid componds
|
|
EP0960096B1
(en)
*
|
1997-01-22 |
2005-04-06 |
Aventis Pharmaceuticals Inc. |
Substituted beta-thiocarboxylic acids
|
|
JP2000507975A
(ja)
*
|
1997-02-07 |
2000-06-27 |
ファイザー・インク |
Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
|
|
PT973512E
(pt)
*
|
1997-02-27 |
2004-07-30 |
Wyeth Corp |
N-hidroxi-2-(alquil, aril ou heteroaril sulfanil, sulfinilou sulfonil)-alquil, aril ou heteroarilamidas substituidas na posicao 3 como inibidores de metaloproteinases da matriz
|
|
US6794511B2
(en)
|
1997-03-04 |
2004-09-21 |
G. D. Searle |
Sulfonyl aryl or heteroaryl hydroxamic acid compounds
|
|
WO1998039315A1
(en)
|
1997-03-04 |
1998-09-11 |
Monsanto Company |
Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
|
|
US6380258B2
(en)
*
|
1997-03-04 |
2002-04-30 |
G. D. Searle, L.L.C. |
Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds
|
|
US6362183B1
(en)
|
1997-03-04 |
2002-03-26 |
G. D. Searle & Company |
Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
|
|
US6476027B1
(en)
|
1997-03-04 |
2002-11-05 |
Monsanto Company |
N-hydroxy 4-sulfonyl butanamide compounds
|
|
US6696449B2
(en)
|
1997-03-04 |
2004-02-24 |
Pharmacia Corporation |
Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
|
|
US7115632B1
(en)
|
1999-05-12 |
2006-10-03 |
G. D. Searle & Co. |
Sulfonyl aryl or heteroaryl hydroxamic acid compounds
|
|
AUPO721997A0
(en)
*
|
1997-06-06 |
1997-07-03 |
Queensland Institute Of Medical Research, The |
Anticancer compounds
|
|
US6300514B1
(en)
|
1997-06-25 |
2001-10-09 |
Ono Pharmaceutical Co., Ltd. |
Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient
|
|
BR9814087A
(pt)
*
|
1997-10-17 |
2000-10-03 |
Aventis Pharm Prod Inc |
Processos para mediar a atividade do receptor de ppar-gama, e para tratar uma condição fisiológica em um paciente
|
|
US20010039287A1
(en)
|
1997-11-14 |
2001-11-08 |
Thomas E Barta |
Aromatic sulfone hydroxamic acid metalloprotease inhibitor
|
|
EP1042290A1
(en)
|
1997-11-14 |
2000-10-11 |
G.D. SEARLE & CO. |
Aromatic sulfone hydroxamic acid metalloprotease inhibitor
|
|
US6750228B1
(en)
*
|
1997-11-14 |
2004-06-15 |
Pharmacia Corporation |
Aromatic sulfone hydroxamic acid metalloprotease inhibitor
|
|
IL135586A0
(en)
|
1997-11-21 |
2001-05-20 |
Upjohn Co |
α-HYDROXY, -AMINO, AND HALO DERIVATIVES OF β-SULFONYL HYDROXAMIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
|
|
US6288063B1
(en)
|
1998-05-27 |
2001-09-11 |
Bayer Corporation |
Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
|
|
EP1357109B1
(en)
|
1998-06-18 |
2008-07-23 |
F. Hoffmann-La Roche Ag |
Process for aryl alkyl sulfide
|
|
FR2780402B1
(fr)
*
|
1998-06-30 |
2001-04-27 |
Adir |
Nouveaux composes acides carboxyliques et hydroxamiques inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
US6172064B1
(en)
*
|
1998-08-26 |
2001-01-09 |
Glaxo Wellcome Inc. |
Formamides as therapeutic agents
|
|
US6020358A
(en)
*
|
1998-10-30 |
2000-02-01 |
Celgene Corporation |
Substituted phenethylsulfones and method of reducing TNFα levels
|
|
BR0007784A
(pt)
*
|
1999-01-27 |
2002-02-05 |
American Cyanamid Co |
Composto, método para inibir mudanças patológicas mediadas pela enzima que converte o tnf-alfa (tace) em um mamìfero, composição farmacêutica, e, processo para preparar um composto
|
|
US6800646B1
(en)
|
1999-02-08 |
2004-10-05 |
Pharmacia Corporation |
Sulfamato hydroxamic acid metalloprotease inhibitor
|
|
AP2001002240A0
(en)
|
1999-02-08 |
2001-09-30 |
Searle & Co |
Sufamato hydroxamic acid metalloprotease inhibitor.
|
|
US6583299B1
(en)
|
1999-05-20 |
2003-06-24 |
G.D. Searle & Co. |
α-amino-β-sulfonyl hydroxamic acid compounds
|
|
US6869951B1
(en)
|
1999-07-16 |
2005-03-22 |
Pharmacia Corporation |
Method of changing conformation of a matrix metalloproteinase
|
|
EP1212089B1
(en)
|
1999-08-21 |
2006-03-22 |
ALTANA Pharma AG |
Synergistic combination of roflumilast and salmeterol
|
|
GB9922825D0
(en)
*
|
1999-09-25 |
1999-11-24 |
Smithkline Beecham Biolog |
Medical use
|
|
US6667316B1
(en)
|
1999-11-12 |
2003-12-23 |
Celgene Corporation |
Pharmaceutically active isoindoline derivatives
|
|
GB9929979D0
(en)
|
1999-12-17 |
2000-02-09 |
Darwin Discovery Ltd |
Hydroxamic acid derivatives
|
|
US6326388B1
(en)
|
1999-12-21 |
2001-12-04 |
Celgene Corporation |
Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
|
|
US6699899B1
(en)
|
1999-12-21 |
2004-03-02 |
Celgene Corporation |
Substituted acylhydroxamic acids and method of reducing TNFα levels
|
|
US6683093B2
(en)
|
2000-05-12 |
2004-01-27 |
Pharmacia Corporation |
Aromatic sulfone hydroxamic acids and their use as protease inhibitors
|
|
AU5652001A
(en)
*
|
2000-05-15 |
2001-11-26 |
Darwin Discovery Limited |
Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
|
|
EP1292576A1
(en)
|
2000-05-15 |
2003-03-19 |
Darwin Discovery Limited |
Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
|
|
FR2809623B1
(fr)
*
|
2000-06-05 |
2003-09-05 |
Sanjuan Benito Arranz |
Dans le traitement des maladies neurodegeneratives : (notamment alzheimer et parkinson), utilisation pour un medicament : du sildenafil (ou de ses derives)
|
|
US8030343B2
(en)
|
2000-06-08 |
2011-10-04 |
Celgene Corporation |
Pharmaceutically active isoindoline derivatives
|
|
US7842727B2
(en)
*
|
2001-03-27 |
2010-11-30 |
Errant Gene Therapeutics, Llc |
Histone deacetylase inhibitors
|
|
US6495719B2
(en)
*
|
2001-03-27 |
2002-12-17 |
Circagen Pharmaceutical |
Histone deacetylase inhibitors
|
|
US7312247B2
(en)
|
2001-03-27 |
2007-12-25 |
Errant Gene Therapeutics, Llc |
Histone deacetylase inhibitors
|
|
US8026280B2
(en)
|
2001-03-27 |
2011-09-27 |
Errant Gene Therapeutics, Llc |
Histone deacetylase inhibitors
|
|
CN1764655A
(zh)
|
2001-05-11 |
2006-04-26 |
法马西亚公司 |
芳族砜异羟肟酸酯及其作为蛋白酶抑制剂的用途
|
|
US6683078B2
(en)
|
2001-07-19 |
2004-01-27 |
Pharmacia Corporation |
Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
|
|
PE20030701A1
(es)
|
2001-12-20 |
2003-08-21 |
Schering Corp |
Compuestos para el tratamiento de trastornos inflamatorios
|
|
MXPA04010555A
(es)
|
2002-04-25 |
2005-02-17 |
Pharmacia Corp |
Acidos piperidinil- y piperazinil-sulfonilmetil hidroxamicos y su uso como inhibidores de proteasa.
|
|
TW200406197A
(en)
*
|
2002-04-25 |
2004-05-01 |
Ono Pharmaceutical Co |
Therapelitic agent for inflammatory bowel disease containing hydroxamic acid as effective component
|
|
WO2003099272A1
(en)
*
|
2002-05-22 |
2003-12-04 |
Errant Gene Therapeutics, Llc |
Histone deacetylase inhibitors based on alpha-ketoepoxide compounds
|
|
MXPA05000171A
(es)
*
|
2002-06-25 |
2005-04-08 |
Pharmacia Corp |
Acido arilsulfonilhidroxamico y derivados de amida y su uso como inhibidores de la proteasa.
|
|
WO2004046104A2
(en)
*
|
2002-11-20 |
2004-06-03 |
Errant Gene Therapeutics, Llc |
Treatment of lung cells with histone deacetylase inhibitors
|
|
EP2181704B1
(en)
|
2002-12-30 |
2015-05-06 |
Angiotech International Ag |
Drug delivery from rapid gelling polymer composition
|
|
TW200418806A
(en)
|
2003-01-13 |
2004-10-01 |
Fujisawa Pharmaceutical Co |
HDAC inhibitor
|
|
MXPA05010373A
(es)
|
2003-04-01 |
2005-12-05 |
Applied Research Systems |
Inhibidores de fosfodiesterasas en infertilidad.
|
|
ES2433440T3
(es)
|
2003-04-04 |
2013-12-11 |
Yeda Research And Development Co. Ltd. |
Anticuerpos contra MMP2 o MMP9 y composiciones farmacéuticas que contienen los mismos útiles para inhibir la actividad de dichas metaloproteínas
|
|
US7244759B2
(en)
|
2004-07-28 |
2007-07-17 |
Celgene Corporation |
Isoindoline compounds and methods of making and using the same
|
|
CA2587013A1
(en)
*
|
2004-11-08 |
2006-05-18 |
Errant Gene Therapeutics, Llc |
Histone deacetylase inhibitors
|
|
KR20080091297A
(ko)
|
2006-02-07 |
2008-10-09 |
아스텔라스세이야쿠 가부시키가이샤 |
Ｎ-히드록시아크릴아미드 화합물
|
|
WO2008147480A2
(en)
*
|
2007-02-01 |
2008-12-04 |
Panthera Biopharna, Llc. |
Hydroxamic acid derivatives of 3-phenyl propionic acids useful as thrapeutic agents for treating anthrax poisoning
|
|
US7879911B2
(en)
|
2007-02-01 |
2011-02-01 |
Johnson Alan T |
Hydroxamic acid derivatives of phenoxy-acetic acids and analogs useful as therapeutic agents for treating anthrax poisoning
|
|
KR20090113908A
(ko)
|
2007-02-23 |
2009-11-02 |
예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 |
금속단백질 활성 억제용 항체 및 이를 함유하는 약학적 조성물
|
|
WO2016128131A1
(en)
*
|
2015-02-09 |
2016-08-18 |
National And Kapodistrian University Of Athens |
Beta-lactone inhibitors of phospholipase a2 and uses thereof
|
|
EP3860608A1
(en)
|
2018-10-04 |
2021-08-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Egfr inhibitors for treating keratodermas
|